Satellite glial cells in dorsal root ganglia are activated in streptozotocin-treated rodents

Menachem Hanani a, Erez Bluma, Shuangmei Liub, *, Lichao Peng b, Shangdong Liang b

a Laboratory of Experimental Surgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
b Department of Physiology, Medical School of Nanchang University, Nanchang, Jiangxi, China

Received: April 6, 2014; Accepted: July 18, 2014

Abstract

Neuropathic pain is a very common complication in diabetes mellitus (DM), and treatment for it is limited. As DM is becoming a global epidemic it is important to understand and treat this problem. The mechanisms of diabetic neuropathic pain are largely obscure. Recent studies have shown that glial cells are important for a variety of neuropathic pain types, and we investigated what are the changes that satellite glial cells (SGCs) in dorsal root ganglia undergo in a DM type 1 model, induced by streptozotocin (STZ) in mice and rats. We carried out immunohistochemical studies to learn about changes in the activation marker glial fibrillary acidic protein (GFAP) in SGCs. We found that after STZ-treatment the number of neurons surrounded with GFAP-positive SGCs in dorsal root ganglia increased 4-fold in mice and 5-fold in rats. Western blotting for GFAP, which was done only on rats because of the larger size of the ganglia, showed an increase of about 2-fold in STZ-treated rats, supporting the immunohistochemical results. These results indicate for the first time that SGCs are activated in rodent models of DM1. As SGC activation appears to contribute to chronic pain, these results suggest that SGCs may participate in the generation and maintenance of diabetic neuropathic pain, and can serve as a potential therapeutic target.

Keywords: diabetes • neuropathic pain • satellite glial cells • glial fibrillary acidic protein

Introduction

Diabetes mellitus (DM) has become a global epidemic, and with the increasing number of patients there is a greater need to understand and treat the manifold problems associated with this disease. A common complication in DM is neuropathy, which affects 50% of the patients and is associated with several serious problems, one of which is chronic pain [1, 2]. The mechanisms of this pain are poorly understood, and therapy is limited [3].

Much of the research on diabetic neuropathy has been done on peripheral mechanisms, and there is strong evidence for major peripheral changes in DM [1, 2]. However, there is also considerable evidence for alterations in the central nervous system in animal models for DM. For example in the db/db mouse model, spinal neurons display abnormal biochemical features, and spinal astrocytes are activated [4]. In the STZ model in rats, spinal microglia undergo activation [5, 6]. These changes are the results of a combination of the peripheral inflammation, hyperglycaemia and the presence of reactive oxygen species in the spinal cord.

An important station in the pain pathways is sensory ganglia, which contain the somata of sensory neurons and satellite glial cells (SGCs) that tightly surround them [7–13]. Neurons in these ganglia generate abnormal (ectopic) firing in a variety of pain states in humans and in animal models, and thus can contribute to chronic pain [7, 14, 15]. It has been therefore stated that the single most important factor in the generation and maintenance of chronic neuropathic pain are increased excitability of primary nociceptive afferents [14]. Changes in dorsal root ganglia (DRG) neurons in DM models have been assessed in several studies, and have shown that ionic channels in DRG neurons are altered [16, 17], suggesting that these ganglia may play a role in diabetic pain. However, there are no reports on possible changes in SGCs in these models.

There is growing interest in the role of glial cells in the central nervous system in chronic pain, and numerous studies showed that in the spinal cord, microglia and astrocytes contribute to the underlying mechanisms [18]. Work in the last decade has demonstrated that SGCs undergo major changes in a large variety of pain models, and that like their central counterparts, they may contribute to chronic
pain [9, 10, 12]. The objective of this work was to test the hypothesis that SGCs are activated in a model of DM1 in mice and rats, and thus may play a role in diabetic neuropathic pain.

Materials and methods

Animals

We used C57bl/6 mice, of either sex (M/F ratio 1:1), and male Sprague-Dawley rats. The procedures were approved by the Animal Care and Use Committees of the Hebrew University and Nanchang University Medical Schools. DM type 1 was induced by an intraperitoneal (i.p.) injection of STZ (single 50 mg/kg for mice; high calorie food and a single STZ 65 mg/kg injection for rats). STZ was dissolved in citrate buffer (pH 4.5). Control animals received buffer. After 7 days blood samples were obtained from the tail vein and glycaemia was determined by using a glucometer. Fasting blood glucose >200 mg/dl (11.1 mM) was considered as DM [19, 20]. At day 14 the animals were killed by CO₂ inhalation, and L4,5 DRGs were removed.

Behavioural study

Individual animals (mice, rats) were placed in a clear plastic box on a wire mesh floor and were allowed to accustom to their new environment for at least 20 min before pain thresholds were assessed by observing withdrawal responses to mechanical stimulation, by using von Frey hairs (Stoelting, Wood Dale, IL, USA). Hairs were applied 10 times at intervals of 5 and 20 s. in ascending order of force. The hairs were pressed against the plantar skin of the hind paw until the hair buckled. Sharp retraction of the stimulated hind paw was considered as a response in the paw. The threshold response was defined when 6 out of 10 responses occurred. Care was taken not to stimulate the same point on the skin in succession.

Immunohistochemistry

Immunohistochemistry was carried out as follows. Mouse DRGs were removed and placed in 4% paraformaldehyde for 2 h at room temperature. The DRGs were then washed in 0.1 M PBS before incubation in 30% sucrose in PBS overnight before freezing in Tissue-Tek embedding medium (Sakura Finetek, Torrance, CA, USA). Sections were cut 12-μm thick by using a cryostat (Leica CM 1950; Leica Microsystems, Leitz, Wetzlar, Germany) and thaw mounted on slides. Sections were washed in PBS and incubated in blocking solution containing 3% bovine serum albumin (BSA) in PBS with 0.3% Triton X-100 for 60 min. at room temperature. Primary antibody against GFAP (rabbit anti-GFAP; Dako, Copenhagen, Denmark) was diluted 1:400, in PBS containing 1% BSA and incubated on ice for 3 h at room temperature. After being diluted with sample buffer and heated to 95°C, the membrane was blocked with 5% non-fat dry milk for 2 h at room temperature, followed by incubation with primary antibody (chicken anti-GFAP 1:1000, Abcam monoclonal β-actin 1:1000; Advanced Immunochemicals, VB Long Beach, CA, USA) overnight at 4°C. The membrane was incubated with secondary antibody, horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG (1:1000; Beijing Zhongshan Biotech, Beijing, China) for 1 h at room temperature. After washing in 25 mM Tris buffered saline, pH 7.2, plus 0.05% Tween 20, chemiluminescent signals were collected on autoradiography film by using enhanced chemiluminescence kit (Shanghai Pufei Biotech, Shanghai, China). Band intensities were measured by using Image-Pro Plus software (Media Cybernetics company, USA) and normalized to each β-actin internal control. Statistical analysis of the data was performed on SPSS 11.5 software, Chicago, Illinois, USA. All the results were expressed as mean ± SD from at least three independent trials. Six animals were included in each group. Statistical significance was determined by unpaired t-test. P < 0.05 was considered as statistically significant.

Results

Only animals in which STZ treatment elevated fasting blood glucose above 200 mg/100 ml were used for the following studies. The values (in mg/100 ml) at 14 days after STZ injection were for mice 97.8 ± 2.0 in controls, and 38.6 ± 18.8 after STZ treatment (N = 4 for each group). For rats the values were 82.9 ± 11.59 in controls and 430.0 ± 68.0 (N = 6 for each group). The STZ-treated animals showed reduced threshold for mechanical stimulation (Fig. 1), consistent with the presence of DM-like neuropathic pain.

Fourteen days after STZ administration there was a 4-fold increase in the number of neurons surrounded by a ring of GFAP-immunopositive SGCs in ganglia from mice (Fig. 2A and B). Figure 2C shows a quantitative analysis of the data. Similar results were obtained in rats (Fig. 3), where the number of neurons surrounded with GFAP-IR SGCs in DRG from STZ-treated rats increased by 4-fold compared with control rats. In both cases, P < 0.05.
To obtain quantitative information on the changes in GFAP in STZ-treated rats, we carried out a Western blot study. As shown in Figure 4, there was an over 2-fold increase in the amount of GFAP protein, in accord with the immunostaining results.

**Discussion**

Neuropathy and pain are common in DM patients, but the underlying mechanisms have received relatively little attention. We show here for...
We used mice for this work because this species has become the animal of choice in biomedical research because of the numerous mutants and knockouts that are available. We decided to use rats also because rats are still the most frequently used animals in diabetes and pain research, and DRG in these animals have been under extensive investigation for decades. In addition, for biochemical studies rats are usually preferable because larger amounts of tissue can be obtained from them in comparison to mice.

The results for mice and rats were very similar, and in both species STZ administration caused a significant increase in GFAP staining. As the DRG in rats are much larger than in mice, we carried out Western blotting on them, and found that the amount of GFAP was doubled in DM1 model. This similarity in the results adds to the validity of the results and indicates that are likely to hold in other species.

GFAP augmentation is a marker for glial activation, which is accompanied by a variety of pathological changes in these cells. For example, in mouse and rat pain models, activation is associated with a large increase in the number of gap junctions connecting SGCs around different neurons [25–27], and augmented responses to the pain mediator ATP [28]. Other investigators have observed increased cytokine production [13, 29] in SGCs in pain models. We therefore propose that SGCs activation in the DM1 models is associated with other changes that may have functional significance, and may contribute to abnormal neuronal activity, and to behavioural effects.

Acknowledgements

Supported by the Israel Science Foundation (311/07, 508/13), the US-Israel Binational Science Foundation (2011044), the National Natural Science Foundation of China (81171184, 31060139), the second batch of Jiangxi province “Gan Po excellence talent 555 project”-leading talent project and the Educational Department of Jiangxi Province (GJJ13155).

Conflicts of interest

The authors confirm that there are no conflicts of interest.

References

1. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012; 11: 521–34.
2. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013; 93: 137–88.
3. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012; 28(Suppl 1): 8–14.
4. Dauch JR, Yanik BM, Hsieh W, et al. Neuron-astrocyte signaling network in spinal cord dorsal horn mediates painful neuropathy of type 2 diabetes. Glia; 2012; 60: 1301–15.
5. Tsuda M, Ueno H, Kataoka A, et al. Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia; 2008; 56: 378–86.
6. Wang D, Couture R, Hong Y. Activated microglia in the spinal cord underlies diabetic neuropathic pain. Eur J Pharmacol. 2014; 728: 59–66.
7. Devor M. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp Brain Res. 2009; 196: 115–28.
8. Hanani M. Satellite gial cells in sensory ganglia: from form to function. Brain Res Rev. 2005; 48: 457–76.
9. Hanani M. Intercellular communication in sensory ganglia by purinergic receptors and gap junctions: implications for chronic pain. Brain Res. 2012; 1487: 183–91.
Can satellite glial cells be therapeutic targets for pain control? Neuron Glia Biol. 2010; 6: 63–71.

The structure of the perineuronal sheath of satellite glial cells (SGCs) in sensory ganglia. Neuron Glia Biol. 2010; 6: 3–10.

Communication between neuronal somata and satellite glial cells in sensory ganglia. Glia. 2013; 61: 1571–81.

Contribution of the activation of satellite glia in sensory ganglia to pathological pain. Neurosci Biobehav Rev. 2009; 33: 784–92.

The effects of axotomy on neurons and satellite glial cells in mouse trigeminal ganglion. Pain. 2004; 110: 290–8.

The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur J Pain. 2013; 17: 571–80.

The effects of differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem. 2004; 279: 29341–50.

Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci. 2007; 27: 3305–16.

Renal lesions in streptozotocin-induced diabetic rats maintained on onion and capsaicin containing diets. J Nutr Biochem. 1999; 10: 477–83.

Effects of neferine on CCL5 and CCR5 expression in SCG of type 2 diabetic rats. Brain Res Bull. 2013; 90: 79–87.

The contribution of peripheral inflammation upregulates P2X receptor expression in satellite glial cells of mouse trigeminal ganglia: a calcium imaging study. Neuropharmacology. 2011; 61: 739–46.

Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res. 2000; 1: 131–43.

Glia and pain: is chronic pain a gliopathy? Pain. 2013; 154: S10–28.

Evidence for a role of connexin 43 in trigeminal pain using RNA interference in vivo. J Neuropathol Exp Neurol. 2008; 100: 3064–73.

Peripheral inflammation upregulates P2X receptor expression in satellite glial cells of mouse trigeminal ganglia: a calcium imaging study. Neuropharmacology. 2011; 61: 739–46.

Early blockade of injured primary sensory afferents reduces glial cell activation in two rat neuropathic pain models. Neuroscience. 2009; 160: 847–57.

Neuronal somatic ATP release triggers neuron-satellite glial cell communication in dorsal root ganglia. Proc Natl Acad Sci USA. 2007; 104: 9864–9.